This was the stock's second consecutive day of losses.

Kenvue beat analysts' expectations for first-quarter profit and revenue on Thursday as strong demand for its cough-and-cold ...

The Johnson & Johnson spinoff that makes Tylenol and Benadryl, logged earnings growth ahead of expectations, named a new ...

Kenvue Inc. has announced the appointment of Amit Banati as chief financial officer, effective today. He will be responsible ...

Shares of Kenvue rose in early Thursday trading after the maker of Band-Aid, Tylenol, and Listerine reported first-quarter ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Kenvue Inc. maintained its sales expectations for the year while lowering its profitability target as tariffs raise costs.

Barclays analyst Lauren Lieberman maintained a Hold rating on Kenvue, Inc. (KVUE – Research Report) today and set a price target of $23.00. The company’s shares closed last Fr ...

The Neutrogena and Aveeno owner has also increased its 2025 full-year outlook to reflect the impact of costs associated with ...

Kenvue Inc. reported second-quarter earnings that surpassed analyst estimates, while updating its full-year 2025 guidance to account for tariffs and currency headwinds.

Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsSofya Tsinis - Head of Investor RelationsThibaut ...

Shares of Kenvue Inc. KVUE slid 1.80% to $24.00 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 3.26% to 5,844.19 and the ...